CDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital Partners
Portfolio Pulse from
Wohl & Fruchter LLP is investigating the fairness of Avid Bioservices' sale to GHO Capital Partners and Ampersand Capital Partners for $12.50 per share, which is below the $14.00 price target set by analyst Paul Knight of KeyBanc.
November 07, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avid Bioservices is being sold to GHO Capital Partners and Ampersand Capital Partners for $12.50 per share. This price is below the $14.00 target set by KeyBanc analyst Paul Knight, prompting an investigation by Wohl & Fruchter LLP into the fairness of the deal.
The sale price of $12.50 per share is below the analyst target of $14.00, which could indicate undervaluation concerns. The investigation by Wohl & Fruchter LLP suggests potential legal or fairness issues, likely causing investor uncertainty and potential short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100